Glp-1 analog fusion proteins
CA 2528591 C · Owner: Glaesner, Wolfgang · Inventors: Glaesner, Wolfgang; Millican, Rohn Lee Jr.; Vick, Andrew Mark
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life decreased , immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose inhibiting gastric and/or , intestinal motility and inhibiting gastric and/or intestinal emptying or , inhibiting food intake.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 10, 2004 and granted January 8, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 10, 2024.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 10, 2026.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.